Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes.
Adolescent
Adult
Aged
Antibodies, Monoclonal, Humanized
/ adverse effects
Anticholesteremic Agents
/ adverse effects
Apolipoprotein B-100
/ blood
Apolipoprotein B-48
/ blood
Biomarkers
/ blood
Cholesterol
/ blood
Cholesterol, LDL
/ blood
Cholesterol, VLDL
/ blood
Chylomicron Remnants
/ blood
Diabetes Mellitus, Type 2
/ blood
Dietary Fats
/ administration & dosage
Dyslipidemias
/ blood
Female
Humans
Kinetics
Lipoproteins
/ blood
Lipoproteins, VLDL
/ blood
Male
Middle Aged
PCSK9 Inhibitors
Postprandial Period
Proprotein Convertase 9
/ metabolism
Serine Proteinase Inhibitors
/ adverse effects
Time Factors
Treatment Outcome
Triglycerides
/ blood
Young Adult
apolipoprotein
cardiovascular diseases
chylomicrons
evolocumab
kinetics
Journal
Arteriosclerosis, thrombosis, and vascular biology
ISSN: 1524-4636
Titre abrégé: Arterioscler Thromb Vasc Biol
Pays: United States
ID NLM: 9505803
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
pubmed:
29
12
2020
medline:
2
6
2021
entrez:
28
12
2020
Statut:
ppublish
Résumé
Increased risk of atherosclerotic cardiovascular disease in subjects with type 2 diabetes is linked to elevated levels of triglyceride-rich lipoproteins and their remnants. The metabolic effects of PCSK9 (proprotein convertase subtilisin/kexin 9) inhibitors on this dyslipidemia were investigated using stable-isotope-labeled tracers. Approach and Results: Triglyceride transport and the metabolism of apos (apolipoproteins) B48, B100, C-III, and E after a fat-rich meal were investigated before and on evolocumab treatment in 13 subjects with type 2 diabetes. Kinetic parameters were determined for the following: apoB48 in chylomicrons; triglyceride in VLDL Evolocumab had only minor effects on lipoproteins that are involved in triglyceride transport (chylomicrons and VLDL
Identifiants
pubmed: 33356392
doi: 10.1161/ATVBAHA.120.315446
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Anticholesteremic Agents
0
Apolipoprotein B-100
0
Apolipoprotein B-48
0
Biomarkers
0
Cholesterol, LDL
0
Cholesterol, VLDL
0
Chylomicron Remnants
0
Dietary Fats
0
Lipoproteins
0
Lipoproteins, VLDL
0
PCSK9 Inhibitors
0
Serine Proteinase Inhibitors
0
Triglycerides
0
lipoprotein cholesterol
0
very low density lipoprotein triglyceride
0
Cholesterol
97C5T2UQ7J
PCSK9 protein, human
EC 3.4.21.-
Proprotein Convertase 9
EC 3.4.21.-
evolocumab
LKC0U3A8NJ
Banques de données
ClinicalTrials.gov
['NCT02948777']
Types de publication
Clinical Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM